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Objective. To investigate the effect of extent of revascularization in complex high-risk indicated patients (CHIP) undergoing
Impella-protected percutaneous coronary intervention (PCI). Background. Complete revascularization has been shown to be
associated with improved outcomes. However, the impact of more complete revascularization during Impella-protected PCI in
CHIP has not been reported.Methods. A total of 86 CHIP undergoing elective PCI with Impella 2.5 or Impella CP between April
2007 and December 2016 from 2 high volume Italian centers were included. Baseline, procedural, and clinical outcomes data were
collected retrospectively. Completeness of coronary revascularization was assessed using the British Cardiovascular Intervention
Societymyocardial jeopardy score (BCIS-JS) derived revascularization index (RI).The primary end-point was all-causemortality. A
multivariate regressionmodel was used to identify independent predictors of mortality. Results. All patients hadmultivessel disease
and were considered unsuitable for surgery. At baseline, 44% had leftmain disease, 78% had LVEF ≤ 35%, and mean BCIS-JS score
was 10±2. The mean BCIS-JS derived RI was 0.7±0.2 and procedural complications were uncommon. At 14-month follow-up, all-
cause mortality was 10.5%. At follow-up, 67.4% of CHIP had LVEF ≥ 35% compared to 22.1% before Impella protected-PCI. Higher
BCIS-JS RI was significantly associated with LVEF improvement (p=0.002). BCIS-JS RI of ≤ 0.8 (HR 0.11, 95% CI 0.01- 0.92, and
p = 0.042) was an independent predictor of mortality. Conclusions. These results support the practice of percutaneous Impella use
for protected PCI in CHIP. A more complete revascularization was associated with significant LVEF improvement and survival.
1. Introduction
Patients with poor left ventricular (LV) function and complex
coronary anatomy (such as multivessel disease, left main
disease, and last remaining vessel) may be unsuitable for
surgical revascularization due to high risk for periprocedural
complications [1]. Percutaneous coronary intervention (PCI)
is an alternative revascularization strategy in such patients,
commonly referred to as complex high-risk indicated patients
(CHIP) [2]. The use of percutaneous left ventricular assist
devices mayminimize the risk of hemodynamic compromise
during such high risk PCI and allow complete revascular-
ization, thus improving outcomes. The feasibility, safety, and
hemodynamic effects of Impella devices during high-risk PCI
have been demonstrated in the PROTECT-I and PROTECT-
II trials and in multiple real-world studies [3–8].
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Recent meta-analysis by Pasceri et al. suggests improved
outcomes following complete revascularization in patients
with multivessel disease [9]. Importantly, studies suggest
the possibility of complete revascularization during Impella-
protected PCI, resulting in reduced need for repeat revas-
cularizations [10]. The purpose of the present study was to
investigate the effect of extent of revascularization, as assessed
using the BCIS-JS, in CHIP undergoing Impella-protected
PCI in an all comers cohort from two high volume Italian
centers.
2. Methods
2.1. Study Population. This is a retrospective study using a
prospectively maintained database: data of all consecutive
patients undergoing elective Impella-protected PCI from
April 2007 toDecember 2016 in two high-volume (>1000 PCI
per year) Italian cardiac catheterization laboratories. Patients
with cardiogenic shock and acute myocardial infarction
within 24 hours were excluded. According to the hospital
practice at the two centers, the need for Impella-protected
high-risk PCI was assessed based on collegial heart-team
discussion in which the potential benefit of myocardial
revascularization was agreed and surgical revascularization
was considered not feasible. Coronary stenosis ≥70% was
considered significant (≥50% in case of left main coro-
nary artery lesion) by visual assessment on angiogram.
Alternatively, it was assessed by guided by fractional flow
reserve (FFR) or by stress test imaging. All patients provided
written consent to undergo PCI with Impella support after
detailed explanation of the procedural features. Clinical
data, operative risk score (EuroSCORE I), and procedural
data were prospectively collected. Synergy between Percu-
taneous Coronary Intervention with TAXUS and Cardiac
Surgery (SYNTAX) score before and after the procedure
was calculated for all patients without previous coronary
surgery. For the present study, an interventional cardiology
fellow (blinded to patient’s clinical presentation and outcome)
graded the myocardium at jeopardy before and after PCI
using the British Cardiovascular Intervention Society (BCIS)
Jeopardy Score (JS) algorithm [11]. Extent of revascularization
was assessed using the BCIS-JS revascularization index (RI):
(BCIS-JSpre -BCIS-JSpost)/ BCIS-JSpre as previously reported
[12]. Two examples of BCIS-JS RI calculations are provided
in Figures 1(a) and 1(b).
2.2. Impella-Protected PCI. The Impella 2.5 or Impella CP
(after its release in Italy) heart pumps were used and implan-
tation was performed through percutaneous trans-femoral
approach. All patients received iliac-femoral artery axis
assessment by ultrasonography and/or peripheral angiog-
raphy during a pre-PCI work-up. All femoral punctures
were fluoroscopy-guided. Prior to Impella sheath placement,
peripheral angiography (through the radial or contralateral
femoral access selected for PCI) was performed to confirm
the suitability of iliac-femoral arterial axis anatomy. Accord-
ingly, when atherosclerotic burden or tortuosity was high,
the contralateral iliac-femoral axis was assessed and the most
favorable side was chosen for Impella implantation. The pres-
ence of atherosclerotic disease of the iliac-femoral axis with
nonsignificant (<50% diameter) stenosis was not considered
an exclusion criterion. No failure of device implantation was
reported due to the screening process including systematic
iliac-femoral axis assessment.
After femoral artery stick, a 6-8 Fr sheath was inserted.
Then, “pre-closure” technique with suture-based hemostatic
deviceswas used.The “pre-closure” techniquewas performed
with (according to operator’s yield) the Prostar XL10F or
Perclose ProGlide devices (Abbott Vascular Devices, Red-
wood City, CA, USA) and consisted of the suture deployment
before introduction of the (13 Fr or 14 Fr) Impella 2.5 or CP
sheath. After the procedure, Impella was removed and the
sutures were tied by pushing down knot(s) in order to achieve
percutaneous hemostasis. Of note, when using ProGlide, a
double ProGlide pre-closure technique was adopted, based
on sequential insertion of two ProGlide devices rotated in
opposite sides 30-45∘, to create an interrupted X-figure clo-
sure [13]. After dedicated sheath insertion, a 6 Fr diagnostic
catheter (Judkins right or pigtail) was advanced into the
LV and used to place the 300 cm extra-support guidewire
into the LV. Then, the Impella catheter was advanced over
the guidewire through the aortic valve into the LV. Impella
was then activated after removal of the guidewire and LV
assistance maintained throughout the procedure. Our center
started using the pre-closure technique before 2007 and
gaining since then experience in the management of vascular
access with large bore devices resulting in low vascular
complication rate (2%) in our registry. Our experience with
double pre-closure system using Perclose has already been
reported elsewhere [14]. In more recent years, our puncture
technique has undergone further improvements by combin-
ing angiographic and ultrasound guidance [15, 16].
PCI was performed by the radial or (in patients with
unsuitable radial accesses) by contralateral femoral approach
using 6-8 Fr guiding catheters. Selection of guidewires,
balloons, and stents was based operator’s choice. Drug-
eluting stent implantation was the main PCI technique and
debulking with Rotablator was the main adjunctive device
used for severely calcified coronary segments. At the end
of PCI, Impella speed was gradually decreased and patient’s
hemodynamic condition was evaluated. In case of hemody-
namic stability, Impella was immediately removed. In the
case of mechanical hemostasis failures, manual compression
followed by compressive bandage was adopted. Of note,
access-artery angiography to confirm hemostasis and to rule-
out vascular complications was systematically performed.
In all patients, heparin was administered (initial weight-
adjusted intravenous bolus then further boluses administered
in order to keep the activated clotting time between 250
and 300s) and double antiplatelet therapy was started before
PCI initiation and recommended for 12 months. Blood
samples were obtained at 6 and 24 h after the procedure
to measure hemoglobin and creatinine levels. Additional
laboratory exams were performed if clinically indicated. The
occurrence of any complication during the hospital stay was
prospectively recorded into the catheterization laboratory
database.
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Figure 1: British-Cardiovascular-Intervention-Society jeopardy-score (BCIS-JS) calculation examples in a patient with complete (a) and in a
patient with incomplete (b) myocardial revascularization. Patient in (a) showed a significant improvement of left ventricular function, while
patient in (b) died after 6 months of follow-up. Arrows indicate significant coronary stenosis. PCI=percutaneous coronary intervention and
LVEF=left ventricular ejection fraction.
2.3. Procedural and Clinical Outcome Assessment. For the
present study, clinical records were carefully evaluated and
clinical follow-up was obtained by reviewing the outpatient
visit reports or by telephone interview. Access site or bleed-
ing complications were classified according to the Valve
Academic Research Consortium (VARC) and the Bleeding
Academic Research Consortium (BARC) criteria [17, 18].
The primary study end-point was all-cause mortality. Major
adverse cardiac and cerebrovascular events (MACCE) were
defined as the composite of death and/or acute myocardial
infarction (AMI) or target vessel revascularization (either
percutaneous or surgical) or stroke. AMI during follow-
up was defined as the rise and fall of cardiac enzymes
(usually serum high-sensitivity Troponin I) in the presence
of electrocardiogram signs or symptoms compatible with
myocardial ischemia, as described in the third universal
definition of myocardial infarction [19]. Stroke was defined
as any new, permanent, global, or focal neurological deficit
ascertained by a standard neurological examination, lasting
longer than 24 hours or less if evidence of cerebral infarction
was obtained by imaging. In our study renal failure was
defined per the Kidney Disease Improving Global Outcomes
(KDIGO) guidelines as any abnormality of kidney function
(decreased glomerular filtration rate <60 ml/min/1.73m2) or
kidney structure (e.g., kidney transplantation).
2.4. Le Ventricular Function. Echocardiographic assess-
ment of the LV ejection fraction (LVEF), aortic valve, and
the presence of intraventricular thrombus was systematically
performed before the procedure. After the index hospital-
ization, clinical follow-up (with echocardiographic examina-
tion) was systematically recommended. Echocardiographic
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assessment of LV function was performed according to the
biplane method of disk summation (modified Simpson’s
rule) [20]. Changes in LVEF between baseline and post-
PCI (at the longest available echocardiographic examination)
were estimated by calculating the “indexed” LVEF variation,
calculated as (LVEFpre-PCI-LVEFpost-PCI)/LVEFpre-PCI.
2.5. Statistical Analysis. Continuous variables are presented
as mean with standard deviation (SD) and categorical vari-
ables as numbers and percentages. The continuous variables
related to LVEF and BCIS-JS RI were categorised in ter-
tiles. Comparisons of continuous variables across different
groups were performed using Student t test or ANOVA test
(as appropriate). Categorical variables were evaluated using
휒2 test or Fisher’s exact test, as appropriate. Comparisons
between pre-PCI and post-PCI data were performed using
paired t-test. A Cox regression analysis was performed to
identify the independent predictors of mortality among the
main baseline characteristics (age, gender, diabetes, renal
failure, prior myocardial infarction, prior PCI, prior cardiac
surgery, clinical presentation, advanced New York Heart
Association class, EuroSCORE, and BCIS-JS RI). Adjusted
hazard ratios (HR) with associated 95% confidence interval
(CI) were calculated for the significant mortality predictors
and corresponding adjusted survival curves were deter-
mined.A 2-tailed, p-value<0.05was established as the level of
statistical significance. All statistical analyses were performed
using SPSS software v22.0 (IBM Corporation, Armonk, New
York).
3. Results
3.1. Patient Population. FromApril 2007 to December 2016, a
total of 86 patients (mean age 72±10 years, 91.8%men) under-
went Impella protected high-risk PCI at twohigh volume Ital-
ian centers andwere included in the present analysis. Baseline
characteristics of patients are listed in Table 1. Patients were
highly symptomatic with New York Heart Association class
III or IV in 69.7%. They had high prevalence of hyperten-
sion (78%), dyslipidemia (62%), diabetes (44%), previous
myocardial infarction (35%), and previous coronary bypass
grafting surgery (22%). About 58% of patients were admitted
for a non-ST elevation myocardial infarction (NSTEMI).
About 78% had LVEF < 35% (mean 31±9%). All patients had
multivessel disease and 44% had left main disease. The mean
SYNTAX score was 31±10 and mean EuroSCORE I was 9±3.
The extent of jeopardized myocardium was large with mean
pre-PCI BCIS-JS of 10 (score range: 0-12). All patients were
deemed unsuitable for surgery on the basis of heart-team
discussion. The baseline characteristics of the present study
cohort were listed alongside previously published clinical
studies: PROTECT II trial, Europella, and USpella registries
[4–6] (Table 1).
3.2. Procedural and Safety Outcomes. Seventy-four patients
(86%) received hemodynamic support with Impella 2.5 and
12 patients (14%) with Impella CP (Table 2). In majority
of patients (77%), PCI was performed via the radial artery
access. Thirty-five (41%) patients underwent left main PCI
and almost three-quarters of patients were treated on at
least two vessels including bifurcations and diffusely diseased
vessels (Table 2). Thirteen patients (15%) received rotational
atherectomy for heavily calcified lesions. At least one drug
eluting stent was implanted in 83 (96%) patients, and the
remaining 3 (4%) patients received bare metal stents due
to concerns regarding their tolerance for prolonged dual
antiplatelet therapy. Both SYNTAX score and BCIS-JS were
significantly reduced after PCI compared to baseline (from
31±10 to 12±9 and from 10±2 to 3±3 respectively, p < 0.001
for both). Patients had complete revascularization as sug-
gested by mean BCIS-JS revascularization index of 0.7±0.2.
Successful hemostasis was achieved by insertion of double
preimplanted Perclose ProGlide in 63%, Prostar XL in 12%,
and manual compression in 25%.
Bleeding and vascular complications occurred in 14%
and 2%, respectively (Table 3). There were 6 cases of minor
hematomas that required no specific intervention (BARC
Type I), 2 patients required bail-out balloon peripheral angio-
plasty to facilitate hemostasis bymanual-compression (BARC
Type II), and 4 patients had decrease in hemoglobin by >3
g/dL with three of them requiring blood transfusion (BARC
Type III). Two minor vascular complications occurred. One
patient had distal embolization few hours after PCI (acute
lower limb ischemia plus occlusion of lower limb arteries
based on ultrasound examination) and was successfully
managed by urgent peripheral angioplasty on tibial-peroneal
arteries. The other case was an access site vascular injury
consisting of angiographically documented common femoral
artery occlusion after Impella 2.5 pump removal. Since the
patient was asymptomatic, and collateral branches provided
full distal supply (probably due to pre-existing superficial
femoral artery disease), a conservative management was
selected, and the clinical course was uneventful. No other
main procedure-related complication was noticed and a total
of 94% of patients were discharged alive (see below for death
reports).
In our study the median value for the duration of Impella
support was 104 minutes (range 55-3151) and Impella mal-
functions were not reported. Further insights into procedural
hemodynamic behavior and Impella pumpperformancewere
available only in 37 patients [21].
3.3. Le Ventricular Function. Seventy-nine patients (92%)
underwent echocardiography at mean follow-up of 6 months
(range 1-12 months) and significant improvement in LVEF
was observed (31±9% at baseline to 39±9%, p < 0.001). Of
the 79 patients, 27.9% presented with pre-PCI LVEF ≤ 25%,
50% with LVEF of 26-34%, and 22.1% with LVEF of 35-50%.
After PCI, only 9.3%had LVEF≤ 25%, and 23.3%had LVEFof
26-34%. Patients had significant improvement in LVEF post-
Impella-protected PCI with 67.4% having LVEF of 35-50%
(Figure 2).
Among the different preprocedural and procedural fac-
tors, pre-PCI LVEF (p< 0.001) and BCIS-JS revascularization
index (p < 0.001) significantly influenced “indexed” LVEF
variation. In particular, significantly higher indexed LVEF
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Table 1: Baseline characteristics of study population.
Present Study PROTECT II EUROpella USpella
Number of enrolling centres 2 112 10 18
Number of enrolled patients 86 225∗ 144 175
Age (years), mean±SD 72±10 68±11 72±10 70±10
Gender, males/females 79/7 180/45 117/27 74/101
Cardiovascular Risk Factors, n(%)
Hypertension 67 (78) / 97 (67) /
Dyslipidemia 53 (62) / 93 (65) /
Diabetes 38 (44) 117 (52) 62 (43) 82 (47)
Smoking 16 (19) / 61 (42) /
Family history of CAD 16 (19) / / /
Renal Failure∘ 27 (31) 102 (23) 41 (28) 58 (33)
Past Cardiac History, n(%)
Prior MI 30 (35) / 76 (53) 98 (56)
Prior PCI 14 (16) / / 84 (48)
Prior CABG 19 (22) 85 (38) 42 (29) 49 (28)
Clinical presentation, n(%)
STEMI 13 (15) / / /
NSTEMI 50 (58) 55 (37) / /
SA 23 (27) 93 (63) / /
NYHA III-IV, n(%) 60 (70) 151 (67) / 115 (66)
LVEF, mean±SD (%) 31±9 23±6 / 31±17
LVEF ≤35%, n(%) 67 (78) 216 (100) 92 (64)† 121 (69)
EuroSCORE,mean±SD 9±3 9±6 8±3 /
Lower Tertile (3-7) 30 (35)
Mid Tertile 2 (8-10) 30 (35)
Higher Tertile 3 (11-20) 26 (30)
Unsuitable for surgery ‡, n (%) 86 (100) 144 (64) 62 (43) 98 (56)
Angiographic characteristics
Multivessel disease, n (%) 86 (100) / 118 (82) 155 (89)
Left main disease, n (%) 38 (44) 18 (8) 76 (53) § 89(51)
Syntax Score 31±10 30±13 / 37±16
BCIS-JS 10±2 / / /
∗ Randomized Impella arm.
† LVEF <40%
‡On the basis of heart-team discussion.
§PCI on left main coronary artery.
∘ Abnormalities of kidney function (decreased glomerular filtration rate <60 ml/min/1.73m2) or kidney structure (e.g., kidney transplantation).
CAD=coronary artery disease; MI=myocardial infarction; PCI=percutaneous coronary intervention; CABG=coronary artery bypass graft; STEMI=ST
elevation myocardial infarction; NSTEMI=non-ST elevation myocardial infarction; SA= stable angina; NYHA=New York Heart Association; LVEF=left
ventricular ejection fraction; BCIS-JS=The British Cardiovascular Intervention Society myocardial Jeopardy Score.
variation was observed in patients with higher BCIS-JS
revascularization index (p = 0.002) (Figure 3).
3.4. ClinicalOutcome and Its Determinants. Therate ofmajor
adverse cardiac and cerebrovascular events (MACCE) during
mean follow-up of 14 months was 24% (Table 4). A total of
nine deaths (10.5%) occurred during the study. In particular,
one death occurred few hours after procedure due to acute
bare metal stent thrombosis. Four deaths occurred within 30
days from the index procedure: three patients died of pro-
gressive respiratory failure in the presence of refractory heart
failure and severe chronic obstructive pulmonary disease and
one patient (exhibiting persistent electrical instability) died
during ventricular tachycardia ablation attempt. Among the
remaining four patients who died after 30 days, one had
fatal stent thrombosis at 6-months, and three had progressive
congestive heart failure. Repeat PCI was performed in 12
patients (14%) and CABG in 1 patient (1%). AMI occurred
in 6 patients (7%) and no case of stroke was reported.
In the multivariate analysis including all the main base-
line characteristics, EuroSCORE I > 11 (HR 311.8, 95%CI 10.9
to 8952, and p = 0.001) and BCIS-JS revascularization index
of ≤ 0.8 (HR 0.11, 95% CI 0.01 to 0.92, and p = 0.042) were
the only independent predictors of mortality (Table 5). No
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Number of treated vessels
One-vessel PCI 23 (27)
Two-vessel PCI 39 (45)
Three-vessel PCI 24 (28)
PCI on bifurcation 52 (60)
PCI with Rotablator 13 (15)




BCIS-JS Revascularization Index,mean±SD 0.7±0.2
Lower Tertile (0.20-0.50) 28 (33)
Mid Tertile (0.51-0.80) 29 (34)




Impella support duration, min∘ 104 (55-3151)
Haemostasis technique
Double Perclose 54 (63)
Prostar 10 (12)
Manual compression 22 (25)
∗ p<0.001 as compared with baseline values.
∘ value expressed as median with range.
PCI= percutaneous coronary intervention; DES=drug eluting stent; BCIS-JS= the British Cardiovascular Intervention Society myocardial Jeopardy Score.
Table 3: Periprocedural bleeding and vascular complications.
COMPLICATION N=86 (%)
Bleedings (BARC criteria) 12 (14)
Type I 6 (7)
Type II 2 (2)
Type III 4 (5)
Type IV 0
Type V 0
Vascular complications (VARC criteria) 2 (2)
Major vascular complication 0
Minor vascular complication 2
Percutaneous closure device failure 0
BARC= Bleeding Academic Research Consortium; VARC= Valve Academic Research Consortium; see text for detailed description of complications.
significant association was found with residual Syntax Score.
Based onKaplan-Meier analysis, patients withmore complete
revascularization of angiographically significant stenosis (RI
> 0.8 to 1.0) had a survival advantage, both early after
PCI and in the longer term, compared to those with less
revascularization (RI 0.2 to 0.5 or 0.51 to 0.80; p = 0.049)
(Figure 4).
4. Discussion
In this large cohort of patients treated by IMP-protected PCI
in two experienced Italian centers we found that:
(1) Impella-protected PCI in CHIP is associated with
LVEF recovery and very promising survival rates























Figure 2: Le ventricular ejection fraction improvement during the follow-up aer IMP-protected PCI. The figure shows the comparison



























Figure 3: Le ventricular ejection fraction improvement according
to revascularization extent. The figure shows the left ventricular
improvement in patients stratified according to revascularization
extent as evaluated by the British Cardiovascular Intervention
Society Jeopardy Score (BCIS-JS) tertiles. LVEF=left ventricular
ejection fraction.
(2) the extent of the coronary revascularization achieved
during IMP-protected PCI in CHIP is associated with
LVEF recovery and survival.
Collectively, the results of our study suggest that Impella-
protected PCI is an attractive revascularization strategy in
CHIP, leading to favorable outcomes.
All the patients in our study had multivessel disease,
were deemed to be ineligible for surgery, and had higher
prevalence of left main disease as compared to the patients
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Months from intervention
BCIS-JS RI higher tertile (0.81- 1.00)
BCIS-JS RI mid tertile (0.51- 0.80)
BCIS-JS RI lower tertile (0.20 -0.50)
Figure 4: Survival curves according to revascularization extent. The
figure shows the adjusted survival curves in the study population
stratified according to British Cardiovascular Intervention Society
Jeopardy Score (BCIS-JS) revascularization index tertiles. RI= revas-
cularization index.
higher complexity andmortality of patients in routine clinical
practice. The study by Waldo et al. suggested that surgical
ineligibility is common and associated with higher mor-
tality among patients with multivessel or left main disease
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MACCE 21 (24) 90 (41) § 17 (12)
Re-PCI 12 (14) 8 (4) / 1 (1)
CABG 1 (1) 2 (1) 0 †
AMI 6 (7) 27 (12) 0 2 (1)
Stroke 0 2 (1) 1 (1) 1 (1)
All-cause death 9 (10) 27 (12) 8 (6) 7 (4)
∗ Randomized Impella arm
∘Data at longest follow up available in the intention-to-treat population
§ Composite rate of intra- and postprocedural major adverse events (MAEs) at discharge or 30-day follow-up, whichever was longer. The composite primary
end point components included all-cause death, Q-wave or non–Q wave
MI, stroke, or transient ischemic attack, any repeat revascularization procedure, need for a cardiac or a vascular operation, acute renal insufficiency, severe
intraprocedural hypotension requiring therapy, cardiopulmonary resuscitation or ventricular tachycardia requiring cardioversion, aortic insufficiency, and
angiographic failure of PCI.
† Includes PCI or CABG revascularization.
MACCE=major adverse cardiac and cerebrovascular events; PCI= percutaneous coronary intervention; CABG=coronary artery bypass grafting; AMI=acute
myocardial infarction
Table 5: Multivariate analysis for independent predictors of mortality.
P-value Adjusted HR (95% CI)
EuroSCORE
mid tertile vs. lower tertile 0.053 31.4 (1.0-1036.8)
higher tertile vs. lower tertile 0.001 311.8 (10.9-8952.0)
BCIS-JS Revascularization Index
mid tertile vs. lower tertile 0.490 0.38 (0.03-5.83)
higher tertile vs. lower tertile 0.042 0.11 (0.01-0.92)
Other variables this model controlled for: age, gender, diabetes, renal failure, prior MI, prior CABG, NSTEMI, and SA.
MI= myocardial infarction; PCI= percutaneous coronary intervention; CABG=coronary artery bypass grafting; NSTEMI=non ST elevation myocardial
infarction; SA= stable angina; NYHA=New York Heart Association; BCIS-JS= the British Cardiovascular Intervention Society myocardial Jeopardy Score.
undergoing nonemergent PCI [22]. Despite the high risk
of mortality, the survival rate in our study was favor-
able at 90% likely due to more complete revascularization
with Impella-protected PCI. In fact, BCIS-JS derived RI
was an independent predictor of mortality in multivariate
analysis.
The present study assessed the extent of revascularization
using the BCIS-JS, which takes into account the entire
myocardial area at risk [12]. The mean BCIS-JS-derived RI
of 0.7 demonstrates the utility of Impella-protected PCI
in achieving more complete revascularization. The finding
of higher survival with higher RI is in line with previous
study demonstrating survival benefit following complete
revascularization and the prognostic value of BCIS-JS in
predicting mortality in high-risk PCI [12]. Complete revas-
cularization during Impella-protected PCI is likely due to
the greater hemodynamic stability provided by Impella, thus
allowing operators to perform more vigorous procedures
including rotational atherectomy for heavily calcified lesions
[4]. Généreux et al. [23] had previously shown that higher
residual Syntax Score was associated with poor short- and
long-term prognosis in patients with moderate/high risk
acute coronary syndrome. However, their study population
was slightly different from that presented in this study: they
had a lower baseline Syntax Score and only a minority of
patients presented with reduced LV function. While Syntax
Score remains the main tool for risk assessment according to
coronary anatomy complexity our results suggest that BCIS-
JS score and the BCIS-JS derived RI might provide a better
risk evaluation in the work-up of CHIP.
More complete revascularization with Impella-protected
PCI resulted in improvement in cardiac function with about
70%of CHIP having LVEF ≥ 35%.Moreover, BCIS-JS derived
RI significantly influenced “indexed” LVEF variation. This is
a novel finding as previous studies of Impella in high risk
PCI have inferred more complete revascularization based
on reduced need for repeat revascularization [4, 10]. As
demonstrated in previous studies with STEMI and mul-
tivessel disease, complete revascularization was associated
with improved survival outcomes and complications [9, 24],
although our patient population included 58% with non-
STEMI.
Previous studies have documented the safety of Impella
use in high-risk PCI at 30 and 90 days [4, 25]. A substudy of
the PROTECT II trial [26] focused on patients with three-
vessel coronary artery disease and reduced LV function,
Journal of Interventional Cardiology 9
showing improved outcomes when Impella 2.5 was used as
LV support device, compared to intra-aortic balloon pump
(IABP).The composite endpoint of major cardiac events was
significantly lower in the Impella group compared to IABP
group (32.9% vs 42.4% at 30 days and 39.5% vs 51.0% after
90 days of follow-up). However, all-cause death rates, for
which the study was not powered, were similar between the
two groups. Moreover, data regarding Impella supported PCI
in patients undergoing unprotected left main (LM) revascu-
larization have been extrapolated from the USpella registry
[27] demonstrating its feasibility and safety. Although the
analysis was mainly based on patients undergoing LM PCI,
they achieved nearly complete revascularization with low
procedural risk.
Our results demonstrate that protected PCI with Impella
2.5 in CHIP yields acceptable complication rates with a
MACCE rate of 24% at longest follow-up of 14 months.
Furthermore, periprocedural adverse events occurred less
frequently given the uniform adoption of best practices
including careful iliac-femoral axis selection, meticulous
femoral puncture, high radial access use for PCI, early
pump removal with angiographic hemostasis check, use of
suture-based devices preclosure technique, and endovascular
management of vascular complications.
Currently, the role of Impella in the setting of high-
risk procedures has been addressed in expert consensus
documents [1]. The role of mechanical circulatory support
is only minimally addressed in the guidelines, due to lack
of strong evidence. The 2011 ACCF/AHA/SCAI guidelines
[28] state that elective insertion of an appropriate hemo-
dynamic support device as an adjunct to PCI may be
reasonable in carefully selected high-risk patients (class
IIb, level of evidence C). The 2010 ESC guidelines [29]
only suggest that circulatory support should be considered
in nonemergent high-risk PCI procedures—such as for
LM disease, single remaining patent coronary artery, and
complex chronic total occlusions—performed by adequately
experienced operators at centres that have access to cir-
culatory support and on site cardiovascular surgery. No
indications for specific devices (i.e., Impella, ECMO) are
given.
Indeed, more data about Impella supported PCI in
the setting of high-risk patients are needed. However, this
study provides evidence supporting the use of Impella in
CHIP.
4.1. Limitations. Given the observational and retrospective
nature of our study, the findings should be considered
hypothesis generating. Randomized trials are required to
fully validate the findings and establish causality. This is a
study from two centers in Italy with unique geographic and
demographic characteristics and therefore results may not be
generalizable.
4.2. Conclusion. Impella-protected PCI in CHIP is associ-
ated with LVEF improvement. A more complete myocardial
revascularization was associated with LVEF improvement
and better survival.
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